Nature Communications (Jan 2020)
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
- Joanna Achinger-Kawecka,
- Fatima Valdes-Mora,
- Phuc-Loi Luu,
- Katherine A. Giles,
- C. Elizabeth Caldon,
- Wenjia Qu,
- Shalima Nair,
- Sebastian Soto,
- Warwick J. Locke,
- Nicole S. Yeo-Teh,
- Cathryn M. Gould,
- Qian Du,
- Grady C. Smith,
- Irene R. Ramos,
- Kristine F. Fernandez,
- Dave S. Hoon,
- Julia M. W. Gee,
- Clare Stirzaker,
- Susan J. Clark
Affiliations
- Joanna Achinger-Kawecka
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Fatima Valdes-Mora
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Phuc-Loi Luu
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Katherine A. Giles
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- C. Elizabeth Caldon
- Cancer Theme, The Kinghorn Cancer Centre
- Wenjia Qu
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Shalima Nair
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Sebastian Soto
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Warwick J. Locke
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Nicole S. Yeo-Teh
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Cathryn M. Gould
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Qian Du
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Grady C. Smith
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Irene R. Ramos
- Department of Translational Molecular Medicine, John Wayne Cancer Institute
- Kristine F. Fernandez
- Cancer Theme, The Kinghorn Cancer Centre
- Dave S. Hoon
- Department of Translational Molecular Medicine, John Wayne Cancer Institute
- Julia M. W. Gee
- Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University
- Clare Stirzaker
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- Susan J. Clark
- Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research
- DOI
- https://doi.org/10.1038/s41467-019-14098-x
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 17
Abstract
Endocrine therapy resistance occurs often in estrogen receptor positive (ER+) breast cancer. Here, the authors find that 3D epigenome remodelling at ER-bound enhancer-promoter interactions is a key mechanism underlying endocrine resistance.
